GSK catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
December 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 2026Sponsor estimate | NCT06258018Niraparib and Temozolomide in Patients GlioblastomaArmando Santoro, MD · Glioma, Malignant | GSKCollaborator | Phase 1/Phase 2 | Not yet recruiting | Locked | Locked | Locked |
| Dec 31, 2026Sponsor estimate | NCT06635421The Expand Study-Pharmacist Administered Long Acting Cabotegravir + Rilpivirine to Expand Access for People With HIVMetroHealth Medical Center · HIV I Infection | GSKCollaborator | No phase registered | Not yet recruiting | Locked | Locked | Locked |
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT06258018Niraparib and Temozolomide in Patients GlioblastomaArmando Santoro, MD · Glioma, MalignantNot yet recruitingGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimateNo phase registeredNCT06635421The Expand Study-Pharmacist Administered Long Acting Cabotegravir + Rilpivirine to Expand Access for People With HIVMetroHealth Medical Center · HIV I InfectionNot yet recruitingGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 12, 2027Sponsor estimate | NCT07862114A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy ParticipantsGlaxoSmithKline · Healthy Participants | GSKLead | Phase 1 | Not yet recruiting | Locked | Locked | Locked |
| Jan 13, 2027Sponsor estimate | NCT06897527A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)GlaxoSmithKline · Neoplasms, Endometrial | GSKLead | Phase 4 | Not yet recruiting | Locked | Locked | Locked |
- Primary completion Jan 12, 2027Sponsor estimatePhase 1NCT07862114A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy ParticipantsGlaxoSmithKline · Healthy ParticipantsNot yet recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 13, 2027Sponsor estimatePhase 4NCT06897527A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)GlaxoSmithKline · Neoplasms, EndometrialNot yet recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.